Chapter 13 - Saving the Empire Meant Letting Part of It Die
For most of her life, Mara thought inheritance meant preservation.
Keep the company.
Keep the science.
Keep the family name.
Keep the control structure.
Keep the founder’s intent.
Then everything happened, and preservation began looking suspiciously like fear wearing better language.
NorthBridge and revised Valence proposals sat before the special committee.
Both viable.
Neither perfect.
Valence now offered $105 million, reduced side rights, no Victor economics, and a commercialization partnership partly beneficial to the family trust.
NorthBridge offered less cash but cleaner governance and more protection of future family participation.
Nathan Sloan preferred Valence for speed and debt relief.
Lydia Mercer preferred NorthBridge because the science would remain more fully anchored inside the company.
The neutral fiduciary wanted both rigorously compared.
Richard preferred NorthBridge emotionally.
Victor, now sidelined but still fighting, still favored Valence because he believed its scale was best for shareholders and because he could not accept that the company might survive without the version of control he built around.
Mara listened to them all.
Then asked the harder question.
“What if the right answer is neither?”
The room quieted.
Because there was a third option, ugly and previously treated as defeat.
Sell a majority stake in the neuro-regenerative division to a strategic clinical partner while retaining a meaningful minority and long-term collaboration rights.
Not family empire.
Not outside takeover.
Something in between.
The idea had been floated, dismissed, revived, and avoided because it felt like losing the future while admitting the company needed help.
Now Mara asked them to model it seriously.
The analysts did.
And the results were uncomfortable.
A structured majority sale to NorthBridge’s clinical affiliate combined with retained minority participation and research covenants might:
* reduce debt significantly,
* preserve core research identity,
* eliminate the need for exotic trust manipulations,
* and keep enough upside inside Hale Biotech for long-term recovery.
It would also mean admitting the family could not keep everything.
Mara felt her father watching her.
Then she said the sentence he least wanted.
“I think we should stop trying to save the shape of the empire.”
Richard closed his eyes.
Because Richard and Celeste had spent decades building a shape: family-controlled science, founder authority, central legacy.
Mara was saying shape was not the same as substance.
Then she added something that changed the room more than the deal analysis.
“If a company needs women to prove they are not weak before it lets them inherit judgment, then preserving it exactly is not loyalty. It’s surrender.”
Lydia almost smiled.
Nathan Sloan looked as though someone had removed a ceiling from the room.
The neutral fiduciary asked Mara whether she was prepared for the symbolic cost.
Headlines would frame it as partial family retreat.
Analysts would say Hale control weakened.
Victor would claim she sold the future because she could not bear pressure.
Mara thought of the hospital pillow.
Of the courtroom.
Of Celeste’s letter.
Of Richard’s ghost life.
“Let them.”
Then she proposed governance reforms broader than anyone expected:
* rewrite trust language so temporary illness or disability cannot delay active participation absent narrow clinical proof,
* separate family governance from executive succession,
* create an independent oversight channel for capability discrimination,
* and limit any executive from negotiating personal economics alongside strategic asset sales without automatic board review.
Boring reforms.
Vital ones.
Richard listened carefully.
Then asked, almost quietly, “Would your mother have agreed?”
Mara answered honestly.
“Not at first.”
“And eventually?”
She thought of Celeste’s letter.
Maybe.
That was enough.
Then came one last personal shift.
Mara asked Richard if he wanted anything once the dust settled.
A board seat?
Restored founder status?
Public vindication?
He took a long time.
Then said, “You trusting me enough to call me before a lawyer does.”
Not forgiveness.
Not reinstatement.
Ordinary human access.
Mara did not say yes.
She also did not say no.
That was the most he deserved right now.
Then the special committee reached preliminary consensus.
Not final.
Preliminary.
NorthBridge majority partnership structure, with family minority retention and governance reform package, looked best.
Victor responded through counsel with fury.
He accused Mara, Richard, and Thomas of dismantling Celeste’s life’s work through sentimental revisionism.
But privately, without control of the trust and without his side economics, his influence was shrinking fast.
Then Detective Elena Ruiz called.
They had found Luis Ortega.
Alive.
Scared.
And ready to talk.
May you like
Mara had chosen transformation over preservation, but before Hale Biotech could move forward, the missing mechanic could finally answer whether Victor’s violence was only financial—or whether he had reached much farther. In Part 14, Luis Ortega’s testimony would force the family to confront the darkest part of the story.
---
